Ribeiro, J
Thyroid C-cell tumors were documented in animal studies at very high doses, but no human thyroid cancers have been attributed to semaglutide use in over 10 years of clinical data
The DNM Semaglutide Medical Weight Loss Program provides a comprehensive and FDA-approved approach, demonstrating that achieving a healthier weight is within reach for those who seek it
The most common adverse reactions include nausea, vomiting, diarrhoea, abdominal pain, and constipation
Commonly affected areas include the back of the arms, thighs, cheeks, & buttocks
Acting on widely expressed GLP-1 receptors, these drugs influence multiple signaling pathways involved in metabolism, cardiovascular health, neuroprotection, and anti-inflammatory responses